Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/25/2023 | $15.00 | Mkt Outperform | JMP Securities |
| 9/12/2023 | $26.00 | Buy | BTIG Research |
| 7/31/2023 | $29.00 | Outperform | RBC Capital Mkts |
| 6/14/2023 | $26.00 | Buy | B. Riley Securities |
| 6/2/2023 | $30.00 | Outperform | Oppenheimer |
| 5/19/2023 | $25.00 | Overweight | Cantor Fitzgerald |
| 4/7/2022 | $16.00 | Outperform | Robert W. Baird |
| 2/28/2022 | $6.00 | Neutral | Goldman Sachs |
4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)
4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)
4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)
Company to Transfer Stock Exchange Listing from NYSE to Nasdaq Ticker symbol will remain "AMAM" Ambrx Biopharma Inc. (NYSE: AMAM) ("Ambrx" or "the Company") today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange, effective March 16, 2023 after market close. Ambrx's American Depositary Shares are expected to begin trading as a Nasdaq-listed security on March 17, 2023. The Company will retain its current ticker symbol "AMAM". "The listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly-traded company and is an important step that will help facilitate our mission to di
- Company now focused on earlier stage engineered antibody drugs for cancer therapies, including new lead asset ARX517 – - Revised focus and projected cost-reductions expected to extend cash runway into 2025 – - Ambrx to host a conference call today at 5:00 p.m. EST / 2:00 p.m. PST - SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced a strategic reprioritization of its pipeline and provided a corporate update. The strategic assessment considered the company's cash runway, pipeline near term v
SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the company will host a corporate update conference call and live webcast on October 18, 2022 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time, to discuss the company's strategic review of its development pipeline. Individuals interested in listening to the conference call may do so by registering via the webcast link in the investor relations section of the company's website at: www.ambrx.com. To access the call by phone, please use the reg
– Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction. Daniel J. O'Connor, Chief Executive Officer of Ambrx, said, "We want to thank our shareholders for their strong support of this transaction. With a steadfast focus on protein engineering innovation and some of the best ADC talent in t
SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ:AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx's closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion. "We are excited to reach this agreement with Johnson & Johnson for advancing scientific research to treat cancers with high unmet needs," said Daniel J. O'Connor, Chief Executive Officer of Ambrx. "With our deep and unique knowledge of precision engineering of protein ther
15-12G - Ambrx Biopharma, Inc. (0001990550) (Filer)
8-K - Ambrx Biopharma, Inc. (0001990550) (Filer)
EFFECT - Ambrx Biopharma, Inc. (0001990550) (Filer)
4 - Ambrx Biopharma Inc. (0001836056) (Issuer)
JMP Securities initiated coverage of Ambrx Biopharma with a rating of Mkt Outperform and set a new price target of $15.00
BTIG Research initiated coverage of Ambrx Biopharma with a rating of Buy and set a new price target of $26.00
RBC Capital Mkts initiated coverage of Ambrx Biopharma with a rating of Outperform and set a new price target of $29.00
SC 13G/A - Ambrx Biopharma Cayman, Inc. (0001836056) (Subject)
SC 13G - Ambrx Biopharma Inc. (0001836056) (Subject)
SC 13G - Ambrx Biopharma Inc. (0001836056) (Subject)
– Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry
SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced the appointment of Renu Vaish, M.Sc., as Chief Regulatory Officer. Ms. Vaish will be responsible for overseeing and designing the Company's global regulatory strategy and will report to the Company's President and Chief Executive Officer, Daniel J. O'Connor. Ms. Vaish is an experienced leader in U.S. and global regulatory affairs with extensive experience in oncology drug development ranging from pre-clinical to commercial products in many fields, including prostate and breast cancer. She has held senior regulatory leadership positions at Celgene, Merck and Kite Phar
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ:AMAM), today announced the appointment of Jared Kelly as Senior Vice President, General Counsel and Corporate Secretary. After practicing for more than ten years at large corporate law firms, Mr. Kelly brings his extensive experience advising public companies on corporate governance, financing transactions and mergers and acquisitions to Ambrx. He will be responsible for developing and overseeing the legal strategy of the Company and for providing legal guidance to the Company's board of directors, executive management team and other business units. Mr. Kelly is an experienced public company lawyer who